Commercial insight into the pharma and biotech sector.

World Preview 2016 

Now in its third edition, EvaluatePharma's annual World Preview report brings together many of our analyses to give exclusive, top level insights into the expected performance of the industry between now and 2016.

Based on EvaluatePharma's comprehensive coverage of the world's leading pharmaceutical and biotech companies, World Preview 2016 highlights trends in prescription drugs sales, patent risk, R&D spend, global brand sales and therapeutic performance  - plus a brief review of 2009 performance.

World Preview provides a snapshot of the industry in 2016 - this is the first time this data has been available and provides exclusive insights into the new competitive pharma landscape beyond the patent cliff.

      Download World Preview 2016

World Preview 2016 - Analysis Highlights:

  • Worldwide prescription drug sales total $785bn in 2016 with 2.9% (CAGR) over 2009-16
  • Humira world's largest selling product in 2016
  • Over $267bn of sales at risk from patent expirations in 2011-16
  • Teva within top 10 drug companies by 2016
  • Pfizer maintains top spot in 2016 via Wyeth acquisition
  • Global pharmaceutical R&D spend to grow by 2.3% (CAGR) to $145bn by 2016
  • Biotech products fail to overtake small molecule within Top 100 Drugs by 2016
  • Anti-coagulants set to record highest growth of major therapy categories to 2016
  • Sales potential of 2009 new drugs (NMEs) up 34% vs. 2008 cohort of NMEs

3 STEPS TO DOWNLOAD REPORT:

 

1. Click link - World Preview 2016

2. Register your details - or login if a Subscriber or Registered User and then click this link - World Preview 2016

3. Activate your account to download report - we will send you an email with a download link

Contact Us if you experience any problems.